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Abstract
Background—Since 1996, hepatitis A vaccine (HepA) has been recommended for adults at 
increased risk for infection including travelers to high or intermediate hepatitis A endemic 
countries. In 2009, travel outside the United States and Canada was the most common exposure 
nationally reported for persons with hepatitis A virus (HAV) infection.
Objective—To assess HepA vaccination coverage among adults 18–49 years traveling to a 
country of high or intermediate endemicity in the United States.
Methods—We analyzed data from the 2010 National Health Interview Survey (NHIS), to 
determine self-reported HepA vaccination coverage (≥1 dose) and series completion (≥2 dose) 
among persons 18–49 years who traveled, since 1995, to a country of high or intermediate HAV 
endemicity. Multivariable logistic regression and predictive marginal analyses were conducted to 
identify factors independently associated with HepA vaccine receipt.
Results—In 2010, approximately 36.6% of adults 18–49 years reported traveling to high or 
intermediate hepatitis A endemic countries; among this group unadjusted HepA vaccination 
coverage was 26.6% compared to 12.7% among non-travelers (P-values < 0.001) and series 
completion were 16.9% and 7.6%, respectively (P-values < 0.001). On multivariable analysis 
among all respondents, travel status was an independent predictor of HepA coverage and series 
completion (both P-values < 0.001). Among travelers, HepA coverage and series completion (≥2 
doses) were higher for travelers 18–25 years (prevalence ratios 2.3, 2.8, respectively, P-values < 
0.001) and for travelers 26–39 years (prevalence ratios 1.5, 1.5, respectively, P-value < 0.001, P-
value = 0.002, respectively) compared to travelers 40–49 years. Other characteristics 
independently associated with a higher likelihood of HepA receipt among travelers included Asian 
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race/ethnicity, male sex, never having been married, having a high school or higher education, 
living in the western United States, having greater number of physician contacts or receipt of 
influenza vaccination in the previous year. HepB vaccination was excluded from the model 
because of the significant correlation between receipt of HepA vaccination and HepB vaccination 
could distort the model.
Conclusions—Although travel to a country of high or intermediate hepatitis A endemicity was 
associated with higher likelihood of HepA vaccination in 2010 among adults 18–49 years, self-
reported HepA vaccination coverage was low among adult travelers to these areas. Healthcare 
providers should ask their patients’ upcoming travel plans and recommend and offer travel related 
vaccinations to their patients.
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1. Introduction
Hepatitis A is caused by infection with the hepatitis A virus (HAV). HAV infection is 
transmitted primarily through the fecal–oral route by either person-to-person contact or 
ingestion of contaminated food or water [1–7]. HAV is endemic in many parts of the 
developing world, where poor sanitation facilitates transmission of the virus [1]. In areas 
where HAV infection is endemic, transmission occurs most frequently among close contacts, 
particularly within households and among extended family settings. In the developed world, 
the incidence of hepatitis A disease is generally low; cases occur in the context of 
community-wide outbreaks transmitted among preschool and school-age children to their 
adult contacts, or in foodborne outbreaks [2–6]. Cases also occur among injection drug users 
and men who have sex with men. In countries with childhood hepatitis A (HepA) 
vaccination programs, an increasing proportion of cases occur among travelers returning 
from hepatitis A endemic areas [1–7].
HAV infection among adults results in substantial morbidity, medical costs and work loss. In 
2007, approximately 35% of persons with acute HAV infection were hospitalized in the 
United States, most of whom were adults and the severity of diseases increased with age 
[2,3,6]. Adults with HAV infection lose an average of 16 work days for outpatients, and 33 
days for hospitalized patients [8].
Persons from the United States who travel to developing countries are at substantial risk for 
HAV infection [5]. Such persons include tourists, military personnel, missionaries, foreign-
born persons who return to their country of origin to visit friends or relatives, and others 
who work or study abroad in countries with high or intermediate HAV endemicity [5]. 
Hepatitis A remains one of the more common vaccine-preventable diseases acquired during 
travel [9,10]. Among acute hepatitis A cases reported nationally for whom travel 
information was available in 2009, 15% involved travel outside the United States and 
Canada even though there were a large number of cases with missing or unknown exposure 
[6]. Similar proportions of travel related hepatitis A cases are reported in Europe [1,11,12]. 
One study estimated the risk of acquiring HAV infection among persons who were not 
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vaccinated before departure to be four to 30 cases per 100,000 months of stay in developing 
countries [13]. In addition, persons who acquire HAV during travel can transmit the 
infection to susceptible persons upon their return [5].
Optimal use of vaccination can significantly reduce the hepatitis A disease burden [5]. In 
1995, the first hepatitis A vaccine was available in the United States. In 1996, the Advisory 
Committee on Immunization Practices (ACIP) recommended hepatitis A vaccination for 
travelers to or persons working in countries with high or intermediate HAV endemicity [14]. 
Men who have sex with men (MSM), injection- and non-injection-drug users, persons who 
have occupational risk for infection, persons with chronic liver disease, and persons who 
have clotting-factor disorders were also recommended for vaccination [14]. In 2006, ACIP 
recommended that all children should receive hepatitis A vaccine at age 1 year (i.e., 12–23 
months); children who are not vaccinated by age 2 years can be vaccinated at subsequent 
visits; states, counties, and communities with existing hepatitis A vaccination programs for 
children aged 2–18 years are encouraged to maintain these programs. In areas without 
existing hepatitis A vaccination programs, catch-up vaccination of unvaccinated children 
aged 2–18 years can be considered; and adult high-risk populations which HepA vaccination 
was recommendation in 1996 were also recommended to receive vaccination in the 2006 
ACIP recommendation [5]. Previous studies showed that HepA vaccination coverage was 
81.2% among children 19–35 months, 42.0% among adolescents, and 34% among MSM 
(high-risk adult population) [15–17].
This study used data from the 2010 National Health Interview Survey (NHIS) to address and 
examine the following questions: [1] What is the most recent HepA vaccination coverage 
among adults 18–49 years who reported travel to a country of high or intermediate HAV 
endemicity? [2] What factors significantly affect HepA vaccination among adults 18–49 
years who reported travel to a country of high or intermediate HAV endemicity?
2. Methods
We analyzed data from the 2010 National Health Interview Survey (NHIS) to determine 
self-reported hepatitis A vaccine (HepA) coverage (≥1 dose) and series completion (≥2 
doses) among adult travelers, 18–49 years, to high or intermediate HAV endemic countries. 
The NHIS is an annual household survey conducted by the National Center for Health 
Statistics of the Centers for Disease Control and Prevention [18]. The NHIS provides 
estimates on health indicators, health care utilization and access, and health-related 
behaviors for the U.S. non-institutionalized, civilian population. The NHIS sample is 
selected through the use of complex sampling design involving stratification, clustering, and 
multistage sampling with a nonzero probability of selection for each person. Estimates were 
weighted to the adult civilian population of the United States. Face to face interviews were 
conducted each week throughout the year in a probability sample of households. Data 
collected over the period of a year form the basis for annual estimates of the health 
characteristics of the U.S. population and the analysis trends in these characteristics. In the 
sample adult core, one adult per sampled family was randomly selected and asked to 
complete the sample adult questionnaire. In 2010, the final response rate for the sample adult 
core was 60.8% [18].
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HepA vaccination coverage was determined using the following sample adult core survey 
question: “The hepatitis A vaccine is given as a two dose series routinely to some children 
starting at 1 year of age, and to some adults and people who travel outside the United States. 
Although it can be given as a combination vaccine with hepatitis B, it is different from the 
hepatitis B shot, and has only been available since 1995. Have you ever received the 
hepatitis A vaccine?” An affirmative answer to the aforementioned question prompted a 
second question concerning how many doses respondents received: “How many hepatitis A 
shots did you receive?” Persons from developed countries who travel to developing countries 
(most of developing countries with high or intermediate HAV endemicity) are at substantial 
risk for acquiring hepatitis A [2,5]. To determine travel status, respondents were asked 
“Have you ever traveled outside of the United States to countries other than Europe, Japan, 
Australia, New Zealand or Canada, since 1995?” For the purposes of this study we will refer 
to travelers to HAV endemic areas as “travelers”.
Vaccination coverage and series completion were stratified by the following demographic 
and other characteristics: travel status (traveled to a country of high or intermediate HAV 
endemicity, not traveled), age group [18–25, 26–29, 40–49], sex (male, female), race/
ethnicity (non-Hispanic white only, non-Hispanic black only, Hispanic, Asian, and others 
(including American Indian/Alaska Native (AI/AN), and multiple race)), marital status 
(married, widowed/divorced/separated, never married), educational level (high school or 
less, above high school), employment status (employed, not employed), poverty level (at or 
above poverty, below poverty), region of residence (Northwest, Midwest, South, West), U.S. 
born status (born in the US, not born in the US), number of physician contacts in the 
previous year (none, 1, 2–3, 4–9, ≥10), hospitalization in the past year (yes, no), place of 
routine health care (clinic or health center, doctor’s office or health maintenance 
organization (HMO)), health insurance status (yes, no), ever lived with hepatitis patients 
(yes, no), ever had chronic liver diseases (yes, no), HepB vaccination (yes, no), influenza 
vaccination in the past year (yes, no), and behavioral risk level for hepatitis B infection (high 
risk or non-high risk). Since persons from developed countries who travel to developing 
countries (most of developing countries with high or intermediate HAV endemicity) are at 
substantial risk for acquiring hepatitis A [2,5], we considered persons who traveled outside 
the United States to countries other than Europe, Japan, Australia, New Zealand, or Canada 
as having traveled to countries with high or intermediate HAV endemicity. Behavioral risks 
for HBV infection were included in the analysis because it includes persons who are 
indicated for HepA vaccination (MSM, IDU), with the caveat that it also includes others 
with behavioral risk for HIV and HepB which are not indications for HepA vaccination. 
Individuals with behavioral risks for HBV infection were defined as persons who considered 
themselves at high risk for HIV infection, or reported having a sexually transmitted disease 
other than HIV/AIDS during the previous five [5] years, or reported any one of the following 
risk factors: male sex with men, injection of street drugs, ever traded sex for money or drugs, 
HIV positive, ever had sex with someone with any of the aforementioned risk factors, and 
hemophilia with receipt of clotting factor concentrates. Non-high risk individuals were 
defined as persons without any of the aforementioned risk factors. All variables listed above 
in the bi-variable analysis were also included multivariable model except for HepB 
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vaccination because of the significant correlation between receipt of HepA vaccination and 
HepB vaccination could distort the model.
We used SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, 
NC) to calculate point estimates and 95% confidence intervals (CIs) of vaccine coverage and 
series completion [19]. All analyses were weighted to reflect the age, sex, and race/ethnicity 
of the U.S. non-institutionalized, civilian population. Bi-variable analysis was conducted 
using a chi-square to test population distributions between travelers and non-travelers. We 
used chi-square tests to test the difference in vaccination coverage and series completion by 
travel status and within each demographic and other characteristic category. Logistic 
regression was used to determine adjusted vaccination coverage and series completion rates 
(i.e., the predictive margins) among travelers only. Predictive margins are a type of direct 
standardization that averages the predicted values from the logistic model, controlling for 
potential confounders [20,21]. A separate logistic regression model was conducted among 
all persons 18–49 years including travel status as an independent variable to determine if 
travel status was an independent predictor of vaccination.
3. Results
The 2010 NHIS surveyed 14,755 adults 18–49 years; 5,561 (36.6%) reported traveling to a 
country of high or intermediate HAV endemicity. The overall population was largely non-
Hispanic white (62.8%), insured (75.0%), employed (72.2%), had greater than a high school 
education (61.7%) and lived at or above the federal poverty line (83.1%). Distribution of 
travelers and non-travelers differed by employment status, poverty level, health insurance, 
and U.S. born status (Table 1). Distribution of travelers and non-travelers also differed by 
most other socio-demographic and access to care characteristics (Table 1). Overall, 29.7% 
travelers 18–49 years were not born in the United States (Table 1), and 26.9% of those were 
Asian (data not shown).
3.1. Bivariate analysis of HepA coverage (≥1 dose) and series completion (≥2 doses)
HepA coverage (≥1 dose) is shown in Table 2. Overall, 26.6% (95% CI = 24.9–28.3%) of 
adult travelers received ≥1 dose of vaccine compared with 12.7% (95% CI = 11.7–13.7%) 
among non-travelers (P-value < 0.001). Series completion (≥2 doses) was also higher among 
travelers at 16.9% (95% CI = 15.4–18.4%) compared with 7.6% (95% CI = 6.8–8.4%) 
among non-travelers (P-value < 0.001) (Table 2).
Among adult travelers, the following characteristics were associated with increased HepA 
coverage on bivariate analysis: younger age (persons 18–25 years had the highest coverage 
and those 40–49 years the lowest); being “Asian” or “other” race/ethnicity; never married; 
having above a high school education; unemployed; increasing number of physician 
contacts; place of routine healthcare being a clinic or doctor’s office or some other place; 
having medical insurance; having a high-risk behavior for hepatitis B infection; ever had 
chronic liver diseases; received influenza vaccination in the previous year; and ever having 
received hepatitis B vaccination. Similar associations were seen among non-travelers and for 
series completion for both travelers and non-travelers.
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3.2. Multivariable analysis of HepA coverage and series completion among travelers
On multivariable analysis among all respondents with travel status as an independent 
variable, coverage (≥1 dose) and series completion (≥2 doses) were higher (prevalence ratios 
2.1, 2.0, respectively, P-values < 0.001) among those who reported travel to a country with 
high or intermediate HAV endemicity compared to non-travelers (data not shown) On 
multivariable analysis among travelers, HepA coverage (≥1 doses) and series completion (≥2 
doses) were higher for travelers 18–25 years (prevalence ratios 2.3, 2.8, respectively, P-
values < 0.001), and for travelers 26–39 years (prevalence ratios 1.5, 1.5, respectively, P-
value < 0.001, P-value = 0.002, respectively) compared to travelers 40–49 years. Other 
characteristics independently associated with a higher likelihood of HepA receipt among 
travelers included Asian race/ethnicity, male sex, never having been married, having a high 
school or higher education, living in the western United States, having greater number of 
physician contacts or receipt of influenza vaccination in the previous year (Table 3). Similar 
associations were seen for series completion, among travelers, with the exception that 
“other” race/ethnicity and sex were no longer statistically significant. Additionally, living in 
the western United States was also independently associated with a higher likelihood of 
HepA receipt in younger age group among travelers and non-travelers (data not shown).
4. Discussion
This study used a representative national survey to assess self-reported HepA vaccination 
coverage among adult travelers to countries of high or intermediate hepatitis A endemicity in 
2010. Travel status was an independent predictor of vaccination HepA coverage (≥1 dose); 
however, series completion (≥2 doses) among adult travelers and non-travelers 18–49 years 
was low. Coverage was higher among younger travelers and travelers who are Asians. In 
addition, male sex, never having been married, having a high school or higher education, 
living in the western United States, having greater number of physician contacts or receipt of 
influenza vaccination in the previous year were independently associated with a higher 
likelihood of HepA vaccination among travelers.
There are several factors that might contribute to low HepA vaccination among travelers to 
HAV endemic countries. Many travelers to nearby international destinations may fail to seek 
travel health advice [13] because of lack of awareness of the risk for travel associated 
infection [22] and travel related vaccination recommendations. Some travelers, such as 
business travelers, journalists and relief workers may be notified of travel on short notice and 
have little time for vaccination prior to departure even though these travelers should be 
vaccinated for planned travel to protect themselves and minimize business costs and liability 
[23]. Travelers’ may believe that travel of short duration, to resorts or on tours, will pose 
little risk of travel related diseases [22]. This belief may also be likely for travelers visiting 
friends and relatives in endemic areas. Low HepA vaccination is a public health issue for 
non-travelers as well (e.g., MSM) in addition to international travelers [5,17,24–26]. 
Additional factors that may contribute to low vaccination coverage include: the historical 
lack of national programs that support vaccine purchase and infrastructure for adult vaccine 
administration and limited private and public sector reimbursement for adult vaccination 
[5,17,24–26].
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Age was strongly associated with reported HepA vaccination among travelers. Our study 
indicated that persons 18–25 and 26–39 years were approximately two to three times more 
likely to report receiving HepA than those 40–49 years after controlling for other 
demographic and access to care variables. Higher vaccination coverage among younger 
adults may be due to one or more factors. First, the incidence of hepatitis A is higher among 
younger adults compared to older adults; higher coverage may reflect a targeted effort by 
health care providers to immunize persons perceived to have greater risk [6,7]. Higher 
vaccination coverage among younger adults 18–25 years may also reflect the aging of the 
cohort of children who were vaccinated under the childhood and adolescent HepA 
vaccination recommendations [2,5,14,25,26].
Coverage was very low among persons 40–49 years at 20% (vaccine coverage) and 12% 
(series completion). Low coverage among older travelers is concerning because persons over 
40 years of age are at greater risk of serious and even fatal consequences of HAV infection. 
Adults over 50 years of age have an approximately sixfold increased risk of death from HAV 
infection [13].
Both race/ethnicity and sex were associated with hepatitis A vaccination among travelers. 
Vaccination coverage was significantly higher among travelers classified as Asian race/
ethnicity. Higher coverage among Asians may, in part, reflect Asians may be vaccinated 
prior to travel to their country of origin to visit family or friends. Male travelers were more 
likely to be vaccinated than their female counterparts. The reason for this disparity may be 
related to other risk factors for HepA vaccination (MSM, IDU). In addition, male travelers 
had a higher employment rate than females and thus may had more chance to have business 
trip and being vaccinated through their employment benefits. The reason for this disparity 
merits further investigation.
Higher education level and increasing number of physician visits per year were both 
associated with HepA receipt among travelers. This result is consistent with other studies of 
adult vaccination [24–29]. In general, persons with less than a high school education 
experience more barriers to health care possibly due to lack of knowledge about preventive 
services [30–32]. It is not surprising that travelers with a greater number of physician 
contacts have higher vaccination coverage, since physician recommendations for vaccination 
are strongly associated with a patient’s decision to get vaccinated [33–35]. Persons who 
have more frequent physician contact also have more opportunities to discuss travel plans 
and receive travel health related advice.
Living in the western United States Region was independently associated with a higher 
HepA receipt among travelers. Higher vaccination coverage was also observed in younger 
age group among travelers and non-travelers in the western United States Region. This result 
may reflect the aging of the cohort of children who were vaccinated under the initial 
childhood and adolescent HepA vaccination recommendations [2,5,14,25,26]. Vaccination 
was recommended initially for children and adolescents among 11 states where hepatitis A 
incidence were substantially higher than other U.S. regions [2,5,14,25,26]. Of those 11 
states, 9 were western states.
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HepB vaccination was significantly associated with higher HepA vaccination coverage 
among travelers in the bi-variable analysis even though HepB vaccination was excluded in 
multivariable model because of the significant correlation between receipt of hepatitis A 
vaccination and hepatitis B vaccination could distort the model. This association may reflect 
providers’ awareness of the possible need for both vaccines among persons traveling to 
countries with high or intermediate HAV and HBV (hepatitis B virus) endemicity [36]. 
Reported receipt of influenza vaccination in the past year was also associated with HepA 
vaccination among travelers. Annual influenza vaccination could provide a platform for 
delivering or recommending HepA vaccine to those who needed and thus may help increase 
vaccination coverage.
To increase vaccination coverage, public health programs and health-care providers are 
encouraged to inform adults receiving preventive clinical services of potential benefits of 
HepA vaccination. Greater vaccination coverage can be achieved by routinely assessing 
patients’ vaccination status, using standing orders for vaccination, incorporating vaccination 
information into electronic medical records, using immunization information systems (IIS) 
[37,38], and reminder-recall systems [35]. Providers should ask their patients’ upcoming 
travel plans and recommend and offer travel related vaccinations to their patients [9]. 
Increased efforts are needed to improve vaccination levels among travelers with lower 
vaccination coverage, particularly travelers 40–49 years or those with lower educational 
levels. Providers should recommend and encourage travelers 40–49 years or travelers with 
lower education to receive vaccination since they are less likely to have been vaccinated. 
Further studies are needed to examine the contribution of other factors so that we can more 
fully understand the complex causes of these patterns and especially ways to overcome 
barriers blocking higher coverage.
The findings in this study are subject to limitations. Data for this study were collected by 
self report and vaccination was not verified by medical records and thus may be subject to 
recall bias or lack of knowledge about the different types of hepatitis vaccines. Thus, 
coverage estimate from the NHIS may under or over report of hepatitis A vaccination among 
both travelers and non-travelers. However, previous studies have found that self-report of 
pneumococcal vaccination by adults was moderately or highly sensitive and moderately 
specific compared with reviews of medical records [39,40], with 1–5% net over-reporting 
bias. Self-report of influenza vaccination by adults also has been shown to have high 
sensitivity and moderate specificity, with 5–11% net over reporting bias [39].
This study documents national hepatitis A vaccination coverage among persons 18–49 years 
reported traveling to a country of high or intermediate endemicity, and underscores the need 
to continue monitoring hepatitis A vaccination coverage. Although travel status was an 
independent predictor of hepatitis A vaccination in our study, HepA vaccination among adult 
travelers to HAV endemic areas was low at approximately 27%. With the passage of the 
Affordable Care Act, all ACIP recommended vaccines would be covered by insurance 
providing greater access to vaccination. To further improve HepA vaccination coverage and 
reduce the burden of travel related HAV infection in the United States, healthcare providers 
are encouraged to adopt strategies to identify candidates for HepA vaccination, and to ensure 
that traveling adults and all adults at increased risk for HAV infection or seeking protection 
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from HAV infection are offered hepatitis A vaccine [5,16,36,41–44]. Travelers, especially 
health travelers with no provider visit, should see their doctor to discuss their travel related 
immunizations and other preventive care services since CDC recommended that 
international travelers should schedule a visit to a primary doctor or a travel medicine 
provider 4–6 weeks before trip [44].
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